Across 4 studies on Lactobacillus amylovorus and reduced inflammation, all 4 reported beneficial effects. Effect sizes were mixed (small to moderate), with the highest-quality study (a meta-analysis) showing a small beneficial effect on C-reactive protein (CRP) reduction. No consistent dose range or single population could be identified due to limited and heterogeneous data.
Caveats: Two of the 4 studies (on Bacillus subtilis and epigallocatechin) do not directly involve Lactobacillus amylovorus supplementation, and one study used human monocytes in vitro. Only the meta-analysis (evidence score 4) directly assessed postbiotic effects on inflammation, reporting a small effect on CRP. Evidence is sparse and heterogeneous.
and C-reactive protein (CRP) (-0.99 mg/L)
XOS generated from MBP-BsXynA11 demonstrated both prebiotic and anti-inflammatory activities in human monocytes.
B. subtilis can also reduce the levels of inflammatory factors (CRP, IL-1β, and IFN-γ) and attenuate the inflammatory response in sows and neonatal piglets.
Supplementation with 12.5 mg/kg EGC (LE) significantly improved growth performance, reduced diarrhea incidence (P < 0.05), enhanced mucosal antioxidant capacity (P < 0.001), and strengthened anti-inflammatory ability (P < 0.001).